Skip to main content
OpenTrials
Completed

NCT Number: NCT00595699

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy. The purpose of the study is to measure the severity and change in depressive and anxiety symptoms after 10 weeks of study treatment with escitalopram or placebo as measured by certain rating scales and questionnaires. In addition, the study will measure the frequency of seizures using a patient diary during the study. Finally, the study will assess the change in the quality of life using rating scales.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

LSU Anxiety and Mood Disorders Clinic

New Orleans, Louisiana, 70115, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has a confirmed diagnosis of temporal lobe epilepsy
  • Subject meets DSM-IV criteria for Major Depression
  • MADRS greater than or equal to 15 at screening and baseline
  • Subject between ages of 18 and 65
  • Female subjects of childbearing potential must take adequate contraceptive precautions (methods with a published failure rate of less than 1% per year, or condom/diaphragm, or diaphragm/spermicide)
  • Subject must provide voluntary signed informed consent approved by the Institutional Review Board of LSU Health Sciences Center

Exclusion criteria

  • Any other primary axis I diagnosis other than Major Depression
  • The presence of psychogenic, non-epileptic seizures
  • A history of non-response to two or more antidepressants given for an adequate therapeutic trial
  • The presence of substance abuse or dependence in past six months
  • The presence of clinically significant malnutrition, cardiac, hepatic or renal disease that might endanger the safety of the subject
  • Pregnancy or nursing
  • Any subjects with suspected mental retardation, psychotic disorder or dementia
  • Subjects whose anticonvulsant medication regimen includes phenobarbital
  • Individuals who will require psychotropic medications such as benzodiazepines or medications likely to cause significant effects on mood or anxiety as outlined in section 5.4
  • Cognitive-behavioral therapy will not be allowed during the course of the study. Other psychotherapeutic modalities (supportive, psychoanalytic, etc.) will be allowed only if the individual has been in therapy for the previous 12 weeks and plans to remain in therapy throughout the duration of the study.
  • Individuals who in the opinion of the investigator would not be able to understand or comply with study requirements
  • Individuals with a known hypersensitivity to escitalopram or any of its ingredients
  • Individuals who in the opinion of the investigator present a significant risk of suicide, or have had a significant suicide attempt in the past two years.

Treatment and study plan

Escitalopram

Drug

10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study

Other names: Lexapro

Placebo

Drug

Placebo

Primary outcomes

  1. Montgomery And Asberg Depression Rating Scale

    Time frame: Screen, Baseline, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 10

Secondary outcomes

  1. Clinician's Global Impression Severity and Improvement subscales

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 10

Sponsors and collaborators

Lead sponsor

Conrad, Erich J., M.D.

Other

Collaborators

  • Forest Laboratories

Registry information

Official study title

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy. A Double-blind, Placebo-controlled Study.

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Jan 16, 2008
Registry last updated
Jul 18, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.